Anti-YB1

0.5mg/ml if reconstituted with 0.2ml sterile DI water. YBX1 (Y box binding protein 1), commonly referred to as YB-1 by researchers, is a human protein. YB1 binding has an absolute requirement for the CCAAT box and relative specificity for the Y box. It has a molecular mass of 35,414 and contains 18% basic residues and putative nuclear localization signals. The YBX1 gene is mapped on 1p34.2. Ybx1 was highly expressed in mouse erythroid myeloid lymphoid clone-1 (EML), a hematopoietic precursor cell line, but that it was downregulated in myeloid progenitors and in Gmcsf-treated EML cells during myeloid differentiation. Ybx1 was expressed at high levels in myeloid leukemic cells at different developmental stages. Knockdown of YBX1 in a human leukemic cell line inhibited proliferation ability, induced apoptosis, and induced megakaryocytic differentiation in response to arsenic trioxide treatment. YBX1 is downregulated during myeloid differentiation and aberrant YBX1 expression in leukemic cells may contribute to leukemia development by blocking differentiation. Protein function: DNA- and RNA-binding protein involved in various processes, such as translational repression, RNA stabilization, mRNA splicing, DNA repair and transcription regulation (PubMed:8188694, PubMed:10817758, PubMed:11698476, PubMed:14718551, PubMed:18809583, PubMed:31358969). Predominantly acts as a RNA-binding protein: binds preferentially to the 5'-[CU]CUGCG-3' RNA motif and specifically recognizes mRNA transcripts modified by C5-methylcytosine (m5C) (PubMed:19561594, PubMed:31358969). Promotes mRNA stabilization: acts by binding to m5C- containing mRNAs and recruiting the mRNA stability maintainer ELAVL1, thereby preventing mRNA decay (PubMed:10817758, PubMed:11698476, PubMed:31358969). Component of the CRD-mediated complex that promotes MYC mRNA stability (PubMed:19029303). Contributes to the regulation of translation by modulating the interaction between the mRNA and eukaryotic initiation factors. Plays a key role in RNA composition of extracellular exosomes by defining the sorting of small non-coding RNAs, such as tRNAs, Y RNAs, Vault RNAs and miRNAs (PubMed:27559612, PubMed:29073095). Probably sorts RNAs in exosomes by recognizing and binding C5-methylcytosine (m5C)-containing RNAs (PubMed:28341602, PubMed:29073095). Acts as a key effector of epidermal progenitors by preventing epidermal progenitor senescence: acts by regulating the translation of a senescence-associated subset of cytokine mRNAs, possibly by binding to m5C-containing mRNAs (PubMed:29712925). Also involved in pre-mRNA alternative splicing regulation: binds to splice sites in pre-mRNA and regulates splice site selection (PubMed:12604611). Also able to bind DNA: regulates transcription of the multidrug resistance gene MDR1 is enhanced in presence of the APEX1 acetylated form at 'Lys-6' and 'Lys-7' (PubMed:18809583). Binds to promoters that contain a Y-box (5'- CTGATTGGCCAA-3'), such as MDR1 and HLA class II genes (PubMed:8188694, PubMed:18809583). Promotes separation of DNA strands that contain mismatches or are modified by cisplatin (PubMed:14718551). Has endonucleolytic activity and can introduce nicks or breaks into double- stranded DNA, suggesting a role in DNA repair (PubMed:14718551). The secreted form acts as an extracellular mitogen and stimulates cell migration and proliferation (PubMed:19483673). [The UniProt Consortium]